Further information will be provided from the ongoing ONCORE trial [104], a prospective, randomized controlled trial enrolling 340 women with breast cancer at early stages scheduled to receive anthracycline and/or anti-HER2 therapy, randomly assigned to participation in a CR program group or a usual care group. The gene discussed is ERBB2; the disease is breast cancer.